百克生物：吸附无细胞百(二组分)白破联合疫苗(成人及青少年用)临床试验申请获得批准

Core Viewpoint - The company, 百克生物 (Biokangtai), has received approval from the National Medical Products Administration for its acellular combined vaccine for adolescents and adults, which targets whooping cough, diphtheria, and tetanus [1] Group 1: Product Approval - The company has been granted a clinical trial approval notice for the acellular combined whooping cough, diphtheria, and tetanus vaccine for adolescents and adults [1] - This vaccine is designed to simultaneously prevent whooping cough, diphtheria, and tetanus in individuals aged 10 years and older [1] - The vaccine aims to stimulate an immune response to prevent invasive infections caused by these diseases [1]